Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study - Ha, MJ; Singareeka Raghavendra, A; Kettner, NM (Int J Cancer, 2022)